Iloperidone (Fanapt): the slow-titration atypical

Iloperidone, sold as Fanapt, was approved by the FDA in 2009 for schizophrenia and received an additional approval in 2024 for acute treatment of bipolar I manic or mixed episodes. It has a relatively low rate of movement side effects and modest weight gain, but its primary clinical challenge is the requirement for slow titration to avoid orthostatic hypotension — meaningful drops in blood pressure on standing that can cause dizziness or fainting.

What iloperidone is

Iloperidone is a piperidinyl-benzisoxazole derivative with antagonist activity at dopamine D2, serotonin 5-HT2A, and notably alpha-1 adrenergic receptors. The strong alpha-1 blockade is responsible both for some of its effectiveness and for its main practical challenge: orthostatic hypotension. The full FDA prescribing information is available through Drugs@FDA.

What it treats

• Schizophrenia in adults
• Acute manic or mixed episodes in bipolar I disorder (as of 2024)

Typical dosing range

The FDA-labelled adult target range for schizophrenia is 12 to 24 mg per day, divided into twice-daily dosing. The starting dose is intentionally low (1 mg twice daily on day 1), with gradual titration over roughly a week to reach therapeutic levels. The slow titration is essential and is the source of most of iloperidone's practical limitations. Specific dosing should always come from your prescriber.

The titration challenge

Most antipsychotics can be started near therapeutic doses on day one. Iloperidone cannot — the alpha-1 blockade causes significant blood pressure drops that the body needs time to adapt to. The label-recommended schedule begins at 1 mg twice daily and increases over about seven days. This means:

• Patients in acute crisis often need a different bridge medication while iloperidone is titrated
• The first week is essentially below therapeutic effect
• If a patient misses doses for more than a few days, the titration may need to be restarted

For these reasons iloperidone is rarely used as a first-line option in acutely ill patients, but it can be an excellent maintenance choice for someone who tolerates it.

Common side effects

• Dizziness — particularly during titration
• Orthostatic hypotension — the defining side effect
• Sedation
• Tachycardia
• Dry mouth
• Nasal congestion
• Mild weight gain

Notably, iloperidone has a low rate of akathisia and other movement side effects compared to many other atypicals — one of its main attractions.

Serious side effects

• QT prolongation — iloperidone produces a meaningful QT effect; baseline ECG is often considered, and combinations with other QT-prolonging medications are avoided
• Tardive dyskinesia (lower rate than first-generation antipsychotics, but possible)
• Neuroleptic malignant syndrome (rare)
• Standard antipsychotic boxed warnings

Drug interactions

Iloperidone is metabolised by CYP2D6 and CYP3A4 enzymes. Patients who are CYP2D6 poor metabolisers (a common genetic variation) have higher iloperidone blood levels and may need lower doses. Strong CYP3A4 or CYP2D6 inhibitors can also raise levels significantly.

What patients commonly say

• "I felt dizzy when I stood up the first week. After that it was fine."
• "It worked without the restlessness I had on aripiprazole."
• "I had to be careful with stairs and standing up."
• "The slow start was frustrating but worth it."

Questions for your prescriber

• How will we manage the titration?
• Should I get a baseline ECG?
• What should I do if I feel dizzy on standing?
• Are any of my other medications going to interact?
• What's the plan if I have to miss doses for any reason?

Putting it together

Iloperidone is a quietly useful atypical with one of the friendlier movement-side-effect profiles in the class. The titration requirement and QT considerations make it less suited to acute crisis use, but for stable maintenance in a patient who tolerates it, it is a reasonable choice. Patient selection and clinician familiarity matter — the medication has been somewhat under-utilised relative to its merits.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.